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Highlights  
 Treatment-resistant depressed groups are rarely studied but may have high inflammation 
 We assessed highly treatment-resistant inpatients before and after admission 
 Findings indicate elevated inflammation in the most treatment-resistant patients 
 High inflammation predicted poorer long-term outcomes after admission 
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Abstract 
 
Background: Treatment-resistant depression (TRD) contributes substantially to the burden of mood 
disorders and is undoubtedly an important subpopulation in whom there are clear unmet treatment 
needs. Despite a paucity of research focusing specifically on TRD, recent studies indicate that 
inflammatory activity may be particularly elevated in these patients.   
Methods: 36 patients with TRD were investigated longitudinally before and after undertaking a specialist 
inpatient treatment program. 27 inflammatory proteins were compared between patients and a matched 
sample of non-depressed controls, as well as between treatment responders and non-responders. 
Treatment outcomes were calculated from depression severity scores before and after admission, and at a 
long-term follow-up 3-12 months after discharge.   
Results: TRD patients had higher levels of numerous inflammatory proteins than controls, and elevated 
interleukins 6 and 8, tumour necrosis factor, c-reactive protein and macrophage inflammatory protein-1 
were associated with poorer treatment outcomes. A separate set of proteins (either anti-inflammatory in 
nature or attenuated at baseline) showed increases during treatment, regardless of clinical response. 
Participants with the greatest elevations in inflammation tended to be older, more cognitively impaired 
and more treatment-resistant at baseline.   
Limitations: The small sample and large number of comparisons examined in this study must be taken 
into account when interpreting these results.  
Conclusions: However, this study provides empirical support for theories that more severe, chronic or 
treatment-resistant depressive disorders are associated with dysregulated inflammatory activity. If a 
predictor or predictors of response in TRD are established, improved and targeted care might be more 
reliably provided to this vulnerable population. 
 
Keywords: inflammation; treatment-resistant depression; cytokines; treatment response 
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Introduction 
Patients with treatment resistant depression (TRD) frequently do not respond to numerous treatments 
and present with chronic, debilitating mood disorders that are often comorbid with many physical and 
mental illnesses (Fekadu et al., 2009a). Despite this serious problem, evidence now suggests that even the 
most treatment-resistant patients can achieve sustained remission with a highly specialist, 
multidisciplinary, intensive and careful intervention program (Wooderson et al., 2014, 2011). Elucidating a 
set of factors that predicts response to treatment will be key to optimising individualised treatment 
choices in both bipolar and unipolar depressive disorders, and for identifying potential new targets for 
novel interventions (Gadad et al., 2018; Strawbridge et al., 2017). Due to the burden of TRD, improving 
outcomes in this population has particular scope to reduce the wider costs associated with depression 
(Fineberg et al., 2013). It has been suggested that TRD patients might have distinct characteristics from 
non-TRD patients (Kornstein and Schneider, 2001), and indirect evidence that dysregulated inflammatory 
activity may be a distinguishing feature (Raison et al., 2013; Strawbridge et al., 2018). Heightened 
inflammation might even represent a common link between treatment resistance and other core 
elements of TRD, such as physical illness or poor physical health (Maes et al., 2011), chronicity and/or 
recurrence of depressive illness (Anisman et al., 1999), cognitive impairments (Li et al., 2018) or early life 
trauma (Grosse et al., 2016). However, these factors are rarely assessed concurrently. Indeed, it has been 
uncommon for investigations of inflammation in mood disorders to assess specifically patients with TRD, 
naturalistic observations of treatment, long-term follow-up assessments, or comprehensive panels of 
inflammatory proteins. The present study explored changes of 32 inflammatory proteins occurring with 
naturalistic treatment for patients with severe TRD and their associations with treatment outcomes.  
In response to existing evidence examining the relationship between inflammation, depression and 
treatment-response, the following main null hypotheses were proposed:  
1) Inflammatory activity will be comparable between TRD patients and a non-depressed control group; 
2) Inflammation will not be associated with clinical response to the inpatient intervention; 
3) Patients’ inflammatory levels will not have changed significantly between pre- and post-treatment. 
Given the size and exploratory nature of this biomarker panel in this population, it was expected that our 
hypotheses would be true for some biomarkers only (anticipated to include the pro-inflammatory markers 
tumour necrosis factor (TNFα), c-reactive protein (CRP) and interleukin-6 (IL-6) based on evidence to date 
(Chamberlain et al., 2018; Maes et al., 1997; Strawbridge et al., 2015).    
 
Methods 
Study Design 
A naturalistic investigation recruited individuals with TRD admitted to a specialist inpatient unit for people 
with treatment-resistant mood disorders (National Affective Disorders Unit, Bethlem Royal Hospital, 
South London and Maudsley NHS Foundation Trust, UK). The unit provided individualised and multi-
disciplinary intervention incorporating pharmacological, psychological, occupational and physical 
therapies where relevant. Research assessments took place upon admission (pre-treatment) and 
discharge (post-treatment) from the unit. A case-control element was additionally employed to compare 
TRD patients with a non-depressed matched control group derived from a population-based study.  
Sample Characteristics   
Patients (n=36): Inpatients were eligible for the study if they met diagnostic criteria for an affective 
disorder (DSM-IV codes 296 or ICD-10 F30-39, assessed using the Mini International Neuropsychiatric 
Interview (Sheehan et al., 1998) and validated by two psychiatrists and had TRD according to the 
Maudsley Staging Method (MSM) multidimensional scale of treatment-resistance (Fekadu et al., 2009b), 
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using the cut-off score of 7.5 indicating TRD (Trevino, 2012) and a Hamilton Rating Scale for Depression 17-
item (HAMD) score >8 (Hamilton, 1960). Treatment completion was defined as >4 weeks of inpatient 
intervention. 
Controls (n=36): Non-depressed volunteers were age-, gender- and BMI-matched individuals without 
current psychiatric disorder, verified using the Clinical Interview Schedule-Revised (Lewis et al., 1992) and 
a Patient Health Questionnaire (PHQ9) score <10 (Kroenke and Spitzer, 2002). The control group were 
participants in a large community investigation; SELCoH study, phase-III (Hatch et al., 2011). Inflammation 
was assessed on one occasion for controls. Patients and controls were matched as closely as possible, to a 
maximum of 2 years difference in age and 5 BMI units. Blood and analysis techniques, and demographic 
data collection were comparable between participant samples. 
This research was conducted in accordance with the Helsinki Declaration (1989) and ethical approval was 
granted by the Camberwell & St Giles NHS (reference 322/03) and King’s College London (reference 
CREC/07/08-152) ethics committees. Participants provided informed written consent before providing 
data.  
Measures 
TRD patients’ depression severity was examined using the HAMD at admission, discharge and a follow-up 
assessment 3-12 months after discharge (long-term outcome). The follow-up assessment may more 
accurately reflect everyday wellbeing following the treatment program, while at discharge HAMD scores 
could dip due to life disruption occurring in the period surrounding this (Wooderson et al., 2011). Short-
term response was defined as HAMD score reduction of >50% between admission and discharge, or if 
criteria for remission were met (HAMD score <8). Long-term outcome was categorised according to 
depressive state at follow-up, with good outcome indicated by absent or sub-threshold depression (HAMD 
0-13) and poor outcome by mild, moderate or severe depression (HAMD 14+). 
At pre-treatment, the following constructs were assessed in TRD patients: Treatment-resistance within 
the current episode using the MSM staging tool; physical health problems using the Modified Cumulative 
Illness Rating Scale (MCIRS (Salvi et al., 2008)); childhood trauma history with the Childhood Trauma 
Questionnaire (CTQ (Bernstein et al., 1994)); cognitive function using the Mini-Mental State Examination 
(MMSE (Folstein et al., 1983)); number of regular pharmacological (psychotropic and non-psychotropic) 
treatments; medication changes (a count for any medication stopped or started during admission). 
Biological Measures 
Peripheral blood samples were collected by antecubital venepuncture and processed for serum 
extraction. After thawing, proteins were simultaneously quantified using ELISA-derived multiplex high-
sensitivity assays (Meso Scale Discovery V-PLEX-Plus kit, Meso Scale Diagnostics, USA). Samples were 
assayed according to manufacturer’s guidelines, with seven-point standard curves run in duplicate to 
calculate absolute concentrations and a no-template control to correct for background fluorescence. 
Patients and control serum samples had been stored for approximately the same time (2-4 years) and had 
not been thawed and refrozen before arrays were run. The two study samples were randomised across 
multiple assay batches; we have found high intra- (r>0.99) and inter-plate (r>0.97) correlations across 
proteins, indicating reliability within this sample. The coefficient of determination demonstrated high 
agreement between concentration and fluorescence signal (r=0.99). The 32 biomarkers measured were: 
CRP, IFNα, IFNγ, IL-10, IL-12, IL-12p70, IL-13, IL-15, IL-16, IL-17, IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8 
(CXCL8), TNFα, TNFβ, Eotaxin (CCL11), Eotaxin-3 (CCL26), GM-CSF, IP-10 (CXCL10), MCP1 (CCL2), MCP4 
(CCL13), Mip1a (CCL3), Mip1b (CCL4), SAA, sICAM1 (sCD54), sVCAM1 (sCD106) and TARC (CCL17). These 
assays have been shown to provide reliable measurement of protein levels in healthy and diseased 
populations (Dabitao et al., 2011). Unless reported otherwise, levels are expressed as picograms per 
millilitre (pg/ml).  
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Data Analysis 
Data Processing:  
Protein data completeness was examined. Where >50% of datapoints were undetected they were 
considered uninterpretable and excluded from analyses. Where <50% fell below the assay’s limit of 
detection, values were imputed with half the lowest level of detection (LLOD), suggested to provide <5% 
discrepancy with true values where 25% of values are undetected and >10% discrepancy where >50% are 
undetected (Croghan and Egeghy, 2003). Data distributions were examined, and biomarker data 
transformed using log-base10 prior to parametric test analysis. Analyses included a bootstrap of 1000 
resamples.  
Main comparisons: 
Addressing main hypotheses, main comparisons focused on inflammatory associations with treatment 
outcomes, over time, and between participant groups.   
1. Biomarkers were compared between TRD and control participants (hypothesis 1) using conditional 
logistic regressions. Where protein distributions affected the fit of regressions, they were first 
standardised using z scores and likelihood ratio tests assessed regressions’ goodness of fit.  
2. To test whether protein levels predicted response (hypothesis 2) at pre- or post-treatment, univariate 
logistic regressions were undertaken.  
3. To assess whether inflammation changed with inpatient treatment (hypothesis 3), 2x2 mixed-factorial 
ANOVA analyses compared pre- and post-treatment levels (response group status was added as a 
between-subjects factor).  
Main comparisons were subjected to a control for multiple comparisons (Simes, 1986); Simes-adjusted p-
values are reported as ‘adjusted’. P-values <0.05 were interpreted as statistically significant.  
Exploratory comparisons: 
Biomarkers were compared between dichotomous subgroups (i.e. bipolar versus unipolar, long-term good 
versus poor outcome, gender, physical ill health) using independent-samples t-tests. Pearson’s 
correlations tested continuous associations with inflammatory markers (depression severity, age, BMI, 
number of medications and changes, childhood trauma, retrospective treatment-resistance, cognitive 
impairment, protein inter-correlations).   
 
Results   
TRD patient characteristics 
As displayed in Table 1, patient characteristics did not differ significantly between responders and non-
responders. All patients completed both pre- and post-treatment clinical assessments (n=36). However, 7 
participants were unavailable for post-treatment venepuncture (post-treatment inflammatory data n=29).   
20 patients (56%) were classified as treatment responders and 16 (44%) as non-responders. In the long-
term, 14 patients had a good outcome (mean HAMD=9.4) and 14 had a poor outcome (mean 
HAMD=19.0).  Patients with a poor long-term outcome were only slightly more like to have been non-
responders than responders at discharge from the inpatient unit (p=0.057).  
All patients were taking multiple combinations of medication on admission (see Supplementary Table 1 
for a detailed summary of medications at admission and changes undergone during the inpatient 
program). After treatment, an increase in antipsychotic medication use could be observed, particularly in 
non-responder patients. The mean number of changes in psychiatric medication (number of agents 
started or stopped during the inpatient stay) was 3.5 for non-responders and 2.1 for responders but these 
did not appear related to inflammatory changes during treatment. In addition to pharmacological 
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therapies, many patients also undertook psychological, occupational or physical therapies. Records of 
these are not sufficiently complete to consider in analyses. No controls were taking NSAIDs. One 
responder was taking low-dose aspirin at both time points. Main comparisons were conducted with and 
without this patient; results were not affected so they were included to maximise statistical power.  
--- Table 1 about here --- 
Inflammatory marker characteristics  
13/32 proteins had undetected values: IFNγ and Eotaxin-3 had <10% undetected; Mip1a, IL-5, TNFβ, IL-
12p70, IL-4 and IFNα had <50% undetected. GM-CSF, IL-13, IL-1β, IL-1α and IL-2 had >50% undetected and 
were excluded from analyses (27 markers analysed). Non-detection was consistently numerically more 
frequent in control than TRD participants, suggesting lower levels in this group and this aligns with 
findings detailed below. Due to the high number of comparisons, Simes correction was conducted on main 
comparisons but due to the potential for this to have rendered putatively important findings non-
significant (Streiner and Norman, 2011) we report significant effects prior to Simes (unadjusted p<0.05) in 
the text below.   
Inflammation in TRD versus control participants 
Table 2 displays baseline comparisons between TRD and non-depressed groups. Unexplained by age, 
gender or BMI, group differences were robust (surviving control for multiple comparisons) for 14 proteins. 
TRD patients had higher Eotaxin-3 (x2(1)=29.53, p=0.001, adjusted p=0.005), IP-10 (x2(1)=27.09, p=0.001, 
adjusted p=0.005), IL-8 (x2(1)=16.61, p=0.002, adjusted p=0.007), IL-5 (x2(1)=24.07, p=0.004, adjusted 
p=0.014), Mip1a (x2(1)=29.54, p=0.001, adjusted p=0.005), Eotaxin (x2(1)=26.54, p=0.001, adjusted 
p=0.005), MCP4 (x2(1)=23.70, p=0.001, adjusted p=0.005), TARC (x2(1)=9.29, p=0.012, adjusted p=0.027), 
IL-6 (x2(1)=4.65, p=0.020, adjusted p=0.042), IL-12 (x2(1)=3.88, p=0.025, adjusted p=0.048).  
IL-16 was also higher in TRD patients, but did not survive Simes control (x2(1)=5.31, p=0.031, adjusted 
p=0.054). sICAM1 (x2(1)=23.71, p=0.001, adjusted p=0.005), sVCAM1 (x2(1)=30.44, p=0.005, adjusted 
p=0.015), MCP1 (x2(1)=5.95, p=0.010, adjusted p=0.025), and TNFβ (x2(1)=8.36, p=0.010, adjusted 
p=0.025) were lower in the TRD group.   
--- Table 2 about here --- 
Inflammatory changes between pre- and post- treatment 
Four inflammatory markers increased over time, although these effects were small and did not survive 
control for multiple comparisons: IL-10 (F(1,27)=4.97, p=0.037), MCP1 (F(1,27)=4.57, p=0.043), sICAM1 
(F(1,27)=4.47, p=0.048) and IFNγ (F(1,27)=7.36, p=0.011). Figure 1 depicts these increases over time and in 
comparison with control levels. Supplementary Table 2 contains results of repeated-measures ANOVA 
tests. 
--- Figure 1 about here --- 
Inflammatory associations with treatment response   
Attenuated pre-treatment IL-7 predicted subsequent non-response, although this was not significant after 
Simes adjustment (x2(1)=4.64, p=0.022, adjusted p=0.616). No other inflammatory markers differed 
significantly between responders and non-responders (see Supplementary Table 3).  
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Inflammatory associations with long-term treatment outcome 
Higher post-treatment pro-inflammatory markers predicted poor longer-term outcomes. Poor outcome 
group-status was predicted by elevated IL-6 (t(20)=3.05, p=0.005) and CRP (t(20)=2.42, p=0.024) as 
displayed in Figure 2, and positive correlations were identified between long-term depression severity and 
TNFa (r=0.47, p=0.026), IL-6 (r=0.51, p=0.016), Mip1a (r=0.43, p=0.047) and IL-8 (r=0.58, p=0.005) at post-
treatment. High pre-treatment MCP4 predicted a poor long-term outcome both between groups 
(t(26)=2.47, p=0.015) and in correlation with long-term severity (r=0.43, p=0.022).  
--- Figure 2 about here --- 
Inflammatory associations with patient characteristics 
The only inflammatory difference between bipolar (n=12) and unipolar (n=24) TRD was higher pre-
treatment IL-4 in patients with unipolar TRD (t(31)= -2.29, p=0.041). The only inflammatory association 
with gender was higher pre-treatment MCP1 in male than female patients (t(34)=2.21, p=0.033). Against 
expectations, only IL-12p70 was correlated with childhood trauma history (post-treatment: r=0.46, 
p=0.032) and only two markers were associated with BMI (IL-6, pre-treatment: r=0.35, p=0.039; post-
treatment: r=0.431, p=0.020 and post-treatment IL-5: r=0.48, p=0.008). Positive associations between 
biomarkers and physical ill health were slightly more frequent; pre-treatment IL-6 (t(34)=2.41, p=0.030), 
IL-15 (t(34)=2.07, p=0.047) and IL-16 (t(34)=3.26, p=0.011).  
Participants with more severe depression at baseline had higher TARC (r=0.38, p=0.024) and IL-4 (r=0.33, 
p=0.048), while discharge CRP was positively correlated with severity (r=0.37, p=0.046). Post-treatment IL-
6 (r=0.56, p=0.002) and IFNa (r=0.42, p=0.025) were higher in those who had more severe depression 
prior to treatment. As shown in Figure 3, severity of retrospective treatment-resistance was greater in 
patients with elevated pre-treatment TNFα (r=0.37, p=0.029), CRP (r=0.35, p=0.039), IL-12 (r=0.36, 
p=0.031) and Mip1b (r=0.35, p=0.034), and post-treatment IL-16 (r=0.42, p=0.025) and TNFβ (r=0.43, 
p=0.019). Additionally, IL-6 correlated positively with treatment-resistance at both pre- (r=0.34, p=0.043) 
and post-treatment (r=0.37, p=0.047). 
--- Figure 3 about here --- 
Older participants had higher inflammation, identified by correlations with CRP at pre-treatment (r=0.40, 
p=0.015) and post-treatment (r=0.25, p=0.046), pre-treatment only with IL-6 (r=0.42, p=0.012), IL-15 
(r=0.39, p=0.018), IL-16 (r=0.52, p=0.001) and SAA (r=0.39, p=0.019) and after treatment only with MCP4 
(r=0.42, p=0.025). Older patients tended to take more medications, and medication load was correlated 
positively with numerous pro-inflammatory markers, albeit at pre-treatment only: with IL-6 (r=0.37, 
p=0.030), CRP (r=0.44, p=0.008), IL-16 (r=0.53, p=0.001), MCP1 (r=0.35, p=0.040), sVCAM1 (r=0.35, 
p=0.040), SAA (r=0.40, p=0.018), Eotaxin-3 (r=0.34, p=0.045) and the anti-inflammatory IL-10 (r=0.38, 
p=0.023). Baseline Eotaxin was higher in those subsequently undergoing more medication changes during 
treatment (r=0.43, p=0.015).  
Lastly, more cognitively impaired patients had higher IL-12 both before (r=0.38, p=0.022) and after 
(r=0.45, p=0.014) treatment. Additional positive associations with cognitive impairment were identified 
for pre-treatment IL-6 (r=0.38, p=0.023), IL-17 (r=0.43, p=0.008) and IFNγ (r=0.51, p=0.001), and for post-
treatment IL-7 (r=0.45, p=0.014), IL-16 (r=0.44, p=0.017), Eotaxin (r=0.46, p=0.013) and IP-10 (r=0.50, 
p=0.006).   
Proteins were frequently inter-correlated, with the acute-phase proteins SAA and CRP most strongly inter-
related (r=0.59, p<0.001) and both strongly correlated with IL-6 and IL-16. IL-6, TNFα and IP-10 most 
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frequently correlated with other proteins at p<0.01. A cluster mainly comprised of chemokines was also 
apparent, including Eotaxin, MCP4, TARC, IL-7 and Mip1b. 
 
Discussion   
There are several routes by which inflammation might play an important role in treatment resistance and 
response in depression. This study demonstrates that patients with TRD have higher proteomic 
inflammatory activity than matched, non-depressed controls and that elevated inflammation is predictive 
of a more severe or resistant depressive illness both retrospectively (i.e. prior to inpatient treatment, in 
the current episode) and prospectively (predicting more severe depressive symptoms in the months after 
discharge). Nonetheless, high inflammation is also indicated in older patients with a greater medication 
load and cognitive impairment, as well as correlating with severity of depression at the time of 
measurement.   
 
Does an inflammatory state predict short-term treatment response?  
Before inpatient intervention, IL-7 is lower in patients who subsequently do not respond to treatment 
before adjustment for multiple comparisons. While this is a novel finding, there are previous reports of 
attenuated IL-7 in MDD than healthy groups, even when controlling for medication and demographics 
(Lehto et al., 2010), and reports of negative correlations between circulating IL-7 and depression severity 
(Einvik et al., 2012; Hall et al., 2016). Despite this, the observed effect is small and short-term outcome is 
not predicted by other inflammatory markers. 
 
Does an inflammatory state predict other measures of a poor clinical outcome? 
Stronger associations are found for inflammation predicting poor long-term outcomes (which may be a 
more valid and relevant parameter in TRD than short-term outcome). TRD patients with a poorer long-
term outcome had higher levels of pro-inflammatory markers, supporting previous findings in MDD for 
common proteins IL-6 (Fornaro et al., 2011), IL-8 (Eller et al., 2009) and CRP (Uher et al., 2014). Similarly, 
heightened TNFa appears associated with unsuccessful antidepressant treatment with support from meta-
analysis (Strawbridge et al., 2015). Few studies have examined MCP4 and Mip1a in depression and this is 
the first evidence to our knowledge of these biomarkers predicting treatment outcome. All these potential 
long-term outcome predictors are prominently involved in upregulating innate immune responses, most 
with chemoattractant properties, suggesting early inflammatory responses may precede more severe 
courses of psychiatric illness (supporting findings of other innate markers predicting response in MDD; 
(Cattaneo et al., 2016).  
In addition to prospective comparisons, cross-sectional correlations between depression severity and 
biomarkers are observed, particularly at pre-treatment for TARC and IL-4, and post-treatment for CRP. 
This pattern suggests that both innate and adaptive immune responses correlate with the severity of TRD.   
 
Does an inflammatory state reflect prior treatment-resistant depression?   
Post-treatment IL-6 and IFNα are higher in patients who were more severely depressed before admission, 
which might reflect a generally more severe illness or pre-existing treatment-resistance in these patients, 
supported by frequent correlations between biomarkers and treatment-resistance assessed using the 
MSM staging tool, which incorporates duration and number of treatments undertaken within the current 
episode alongside severity into multidimensional quantification of TRD (Fekadu et al., 2009b). Each of 
these correlations were positive in direction and predominantly involve pro-inflammatory markers (IL-6, 
TNFα, CRP, IL-12, Mip1b, IL-16, TNFβ). Most of these proteins are higher in TRD than control groups; taken 
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together, these findings support the theory that TRD could represent an ‘inflammatory’ subgroup of 
depression (Raison et al., 2013; Strawbridge et al., 2018) for whom anti-inflammatory treatments may be 
effective (Husain et al., 2017).  
 
Is there an inflammatory state in TRD? 
We replicate previous findings of elevated inflammatory activity (Köhler et al., 2018) in a population of 
treatment-resistant inpatients. 15 of the 27 proteins are significantly different between TRD and control 
participants, and this relationship does not appear affected by age, gender or BMI. Mostly, proteins are 
elevated in TRD (IL-8, IL-6, IL-12, MCP4, Eotaxin, Eotaxin-3, IP-10, Mip1a, IL-5, TARC, IL-16) and these are 
predominantly chemokines not previously been compared between depressed and non-depressed 
populations, to our knowledge (e.g. TARC, Eotaxin-3) and represent new potential targets for this field. In 
the most extensive meta-analysis of cytokines in MDD to date, IL-12 and IL-6 were elevated as we have 
reported, but IL-8, Mip1a and IL-5 were not significantly altered (Köhler et al., 2018) unlike the elevations 
seen in this study. It is possible that these proteins are over-expressed in more chronic affective disorders 
and could implicate Th2 inflammation in this subpopulation.   
sICAM1, sVCAM1 and MCP1 are notably lower in this sample of inpatients than controls, unexpected as 
these chemoattractants function as part of a pro-inflammatory response and have in a few studies been 
reported as elevated in depression (Dimopoulos et al., 2006; Schaefer et al., 2016). Although highly 
speculative, it is possible that low circulating immunoglobulin levels may suggest that they have 
penetrated the blood-brain-barrier into the brain (Takeshita and Ransohoff, 2012), a possibility that we 
were not able to examine.  
The a priori markers of interest TNFα and CRP do not significantly differ between TRD patients and 
controls, in contrast with previous findings (Chamberlain et al., 2018; Köhler et al., 2018; Strawbridge et 
al., 2015) plausibly due to lack of matching between patients and controls in previous studies. Despite this, 
we find evidence of a broad inflammatory state in this group of highly treatment-resistant patients 
characterised by high levels of Th1 and Th2 cytokines and chemokines, alongside suppression of only a 
few inflammatory markers. Certainly, the bidirectionality of our findings suggests a complex relationship 
between TRD and immune responses, which is not exclusively ‘pro-inflammatory’, and may reflect a 
system imbalance. 
 
Is inflammation a state or trait phenomenon in TRD? 
Most cytokines do not change significantly between pre- and post- inpatient timepoints. sICAM1, MCP1, 
IL-10, and IFNγ increase to some degree over time; although this may appear in contrast with theories and 
meta-analyses (Hannestad et al., 2011; Strawbridge et al., 2015) there are a number of potential 
explanations. IL-10 actively downregulates pro-inflammatory responses and the increase may represent a 
resolution of inflammation; sICAM1 and MCP1 were attenuated in TRD patients before treatment and an 
increase may indicate reduced inflammatory imbalance; and IFNγ is often found to be attenuated in MDD 
(Köhler et al., 2018) although not in the present study.    
 
How is inflammation in TRD influenced by other factors?   
Substantial previous research has linked inflammatory markers with numerous factors such as childhood 
trauma, BMI and age, and lack of control for these factors has been postulated as a source of 
inconsistency and heterogeneity in evidence to date (Strawbridge et al., 2017). We do not find differences 
between treatment-responders and non-responders in any of these possible modifying variables.  
As expected, patients with greater retrospective treatment-resistance tended to be older and taking more 
medications. However, most inflammatory associations with treatment-resistance were not those related 
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to medication load, age or physical illness (e.g. TNFa, IL-8, IL-12). Cognitive function is not associated with 
other ageing or health-related factors, but cognitive impairments are greater in the presence of high IL-17, 
IP-10 and IFNγ in particular. This is expected, since chronic inflammation can impair cognition through a 
number of neurobiological routes and is a putative link between affective illnesses and cognitive 
symptoms (Li et al., 2018).  
 
Although this study does not infer causality, both inflammatory aberrations and treatment-resistance may 
develop progressively. A variety of studies have suggested that elevations in oxidative and nitrosative 
stress are associated closely with inflammation and are a key mechanism in maintaining and perpetuating 
future psychopathological processes in a neuroprogressive fashion through e.g. membrane damage (Maes 
et al., 2013). The development of these disruptions to biological processes has been attributed to various 
causes including genetic vulnerabilities (e.g. Czarny et al., 2016) and the experience of severe and/or 
ongoing psychosocial stress (Miller et al., 2009), although there are likely interactive predisposing and 
environmental effects. 
  
Limitations and Strengths 
The exploratory nature of this study carries a number of weaknesses regarding interpretation and 
attribution of findings. Notably, this includes a small sample size and large number of comparisons, as well 
as incomplete follow-up data, non-standardisation of treatments received, the fact that TRD and control 
groups were recruited from different sources and the inability to account for additional factors on 
inflammatory activity.   
The sample size and number of comparisons undertaken in this investigation render our findings 
vulnerable to false positive and/or false negative (masked) results. Employing Simes adjustment for 
multiple comparisons lessened the risk of type I error, but may have rendered potentially important 
findings non-significant (Streiner and Norman, 2011). We have reported unadjusted p<0.05 in order to 
maintain consideration of these tentatively significant results. In comparisons where only few markers 
were significant, Simes adjustment resulted in no significant results, deriving partly from the test’s 
assumption that independent variables should be correlated. This biomarker array contains 
heterogeneity; not all proteins are intercorrelated, but we posit that biomarker findings cluster together 
suggesting an overall inflammatory pattern that is relatively coherent. Not all analyses were subject to 
Simes control, many of which have not yet been conducted in depression or TRD: this was considered 
exploratory work which has yielded promising findings.  
Further limitations include the lack of ability to control for acute infection or inflammation, especially due 
to a known physical condition. We attempted to account for use of non-steroidal anti-inflammatory drugs, 
but the possibility of acute inflammatory states biasing findings is not impossible. In addition, the different 
recruitment sources that TRD and control groups originated from resulted in separately assayed samples 
across multiple batches. While the assay itself is of high quality, reliability and sensitivity (Dabitao et al., 
2011), factors such as type and length of specimen storage may have induced bias by degradation of some 
biomarkers. Before the array was run, neither patients’ or controls’ serum samples had been thawed and 
refrozen, or were more than 4 years old. Non-detected levels were imputed using half the detection cut-
off (LLOD/2), considered acceptable where levels are likely undetected due to true minimal levels present 
in sera but (as with all single imputation methods) this approach does succumb to reduced variance within 
the sample and due caution should be paid when interpreting IFNγ and Eotaxin-3 (<10% undetected), 
Mip1a, IL-5, TNFβ, IL-12p70, IL-4 and IFNα (10-50% undetected). Notwithstanding the promising results 
identified, future studies should consider these issues throughout the research process.  
The wider array of markers measured is an advantage to this study, permitting a more complete picture of 
inflammatory activity. Consequently, our results indicate more promising biomarkers than are often 
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discussed, which may be important in understanding the pathophysiology of TRD as well as other mood 
disorders, and for using biomarkers to improve clinical care. The large number of potential modifying 
factors measured also enables a more complete understanding of how inflammation is altered in TRD: 
health- and aging-related factors appear most important for controlling in future. Despite being 
naturalistically recruited, our inpatient population may not be representative of the wider population of 
people with TRD, most of whom do not receive such specialist care. However, additional strengths of this 
study include the use of a population-based control group, meaning that our results are less likely to be 
subject to selection bias among controls and in patients, assessment of longer-term outcomes which may 
provide more reliable or valid indicators of treatment success (Wooderson et al., 2014). For pragmatic 
reasons, follow-up was not at a standardised time point and did not contain biological measurement but 
depression at follow-up is found to be more clearly predicted by inflammation than at treatment 
endpoint. 
 
Recommendations and clinical implications 
This examination was not able to take a multivariable approach to predicting treatment-response, which 
will likely provide more valid and replicable predictions through integrating diverse information (e.g. 
inflammatory and clinical variables) rather than considering singular factors (Lee et al., 2018).  
We recommend assessing response at a time after treatment, to evaluate symptoms after any transient 
‘treatment-end’ effects have subsided, and/or measuring response at multiple time points to measure 
continuity of wellbeing; these might represent more valid outcome examination, particularly given the 
tendency of TRD to fluctuate in severity over time (Vergunst et al., 2013).  
Our results support existing theories of inflammation dysregulation in depression, but illustrate that 
factors such as age and medication must be investigated in order to obtain meaningful results. This may 
be particularly important in TRD studies due to associations with reduced physical health and increased 
medication intake. It would be useful for future work to directly compare inflammation in TRD and non-
TRD participants, as well as comparisons between unipolar and bipolar mood disorders, accounting for 
potentially confounding factors. If an inflammatory subtype can be determined and confirmed in future 
work, this has considerable implications for targeting and optimising interventions.  
 
 
Acknowledgements  
We are grateful to the ADU and SELCoH study participants and staff for their time and efforts. We 
appreciate the support of the National Institute for Health Research (NIHR) Biomedical Research Centre 
(BRC) at South London and Maudsley NHS Foundation Trust (SLaM) and King’s College London (KCL). The 
views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the 
Department of Health.  
Author Statement   
 
Contributors  
RS was involved in the study’s conception, data collection, analysis, interpretation and writing of the 
manuscript. JH was involved with statistical analysis and interpretation of data. TP and GB contributed to 
data analysis. MH and SH were involved with study conception and design. AJC was involved with 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
overseeing conception and design as well as data analysis and interpretation. All authors contributed to 
drafting/revising the article and approved the final version for publication.   
 
Role of the Funding Source   
This study represents independent research part-funded by the National Institute for Health Research 
(NIHR) Biomedical Research Centre (BRC) at South London and Maudsley NHS Foundation Trust (SLaM) 
and King’s College London (KCL). The SELCoH study was supported by the Biomedical Research Nucleus 
data management and informatics facility at SLaM, which is funded by the NIHR BRC and a joint 
infrastructure grant from Guy’s and St Thomas’ Charity and the Maudsley Charity. TRP is funded by a 
Medical Research Council Skills Development Fellowship (MR/N014863/1) and biomarker analyses were 
supported by an LRAP grant from Eli Lilly. These funders had no involvement in study design, data 
collection, analysis or the decision to submit for publication.  
 
Acknowledgements  
We are grateful to the ADU and SELCoH study participants and staff for their time and efforts. We 
appreciate the support of the National Institute for Health Research (NIHR) Biomedical Research Centre 
(BRC) at South London and Maudsley NHS Foundation Trust (SLaM) and King’s College London (KCL). The 
views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the 
Department of Health.  
 
  
Declaration of Interest  
AJC has received honoraria for speaking from Astra Zeneca and Lundbeck, honoraria for consulting with 
Allergan, Janssen, Livanova, Lundbeck and Sandoz and support for conference attendance from Janssen 
and research grant support from Lundbeck, in the last 3 years. GB has received consultancy fees and 
funding from Eli Lilly. MH is principal investigator of the RADAR-CNS consortium, a public private 
precompetitive consortium co-funded by European Commission and members of European Federation of 
Pharmaceutical Industries and Associations (EFPIA) including Janssen, Lundbeck, Merck, UCB and Biogen.  
The authors report no further competing interests in this work. 
 
 
References 
 Anisman, H., Ravindran, A.V., Griffiths, J., Merali, Z., 1999. Endocrine and cytokine correlates of major 
depression and dysthymia with typical or atypical features. Mol. Psychiatry 4, 182–188. 
https://doi.org/10.1038/sj.mp.4000436 
Bernstein, D.P., Fink, L., Handelsman, L., Foote, J., Lovejoy, M., Wenzel, K., Sapareto, E., Ruggiero, J., 1994. 
Initial reliability and validity of a new retrospective measure of child abuse and neglect. Am. J. Psychiatry 
151, 1132–1136. https://doi.org/10.1176/ajp.151.8.1132 
Cattaneo, A., Ferrari, C., Uher, R., Bocchio-Chiavetto, L., Riva, M.A., MRC ImmunoPsychiatry Consortium, 
Pariante, C.M., 2016. Absolute Measurements of Macrophage Migration Inhibitory Factor and Interleukin-1-
β mRNA Levels Accurately Predict Treatment Response in Depressed Patients. Int. J. 
Neuropsychopharmacol. 19. https://doi.org/10.1093/ijnp/pyw045 
Chamberlain, S.R., Cavanagh, J., de Boer, P., Mondelli, V., Jones, D.N.C., Drevets, W.C., Cowen, P.J., Harrison, 
N.A., Pointon, L., Pariante, C.M., Bullmore, E.T., 2018. Treatment-resistant depression and peripheral C-
reactive protein. Br. J. Psychiatry J. Ment. Sci. 1–9. https://doi.org/10.1192/bjp.2018.66 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
Croghan, C.W., Egeghy, P.P., 2003. Methods of Dealing with Values Below the Limit of Detection using SAS. 
http://analytics.ncsu.edu/sesug/2003/SD08-Croghan.pdf.  
Czarny, P., Kwiatkowski, D., Toma, M., Gałecki, P., Orzechowska, A., Bobioska, K., Bielecka-Kowalska, A., 
Szemraj, J., Berk, M., Anderson, G., Śliwioski, T., 2016. Single-nucleotide polymorphisms of genes involved in 
repair of oxidative DNA damage and the risk of recurrent depressive disorder. Med Sci Monit,22, 4455. doi:  
[10.12659/MSM.898091] 
Dabitao, D., Margolick, J.B., Lopez, J., Bream, J.H., 2011. Multiplex measurement of proinflammatory cytokines 
in human serum: comparison of the Meso Scale Discovery electrochemiluminescence assay and the 
Cytometric Bead Array. J. Immunol. Methods 372, 71–77. https://doi.org/10.1016/j.jim.2011.06.033 
Dimopoulos, N., Piperi, C., Salonicioti, A., Mitsonis, C., Liappas, I., Lea, R.W., Kalofoutis, A., 2006. Elevation of 
plasma concentration of adhesion molecules in late-life depression. Int. J. Geriatr. Psychiatry 21, 965–971. 
https://doi.org/10.1002/gps.1592 
Einvik, G., Vistnes, M., Hrubos-Strøm, H., Randby, A., Namtvedt, S.K., Nordhus, I.H., Somers, V.K., Dammen, T., 
Omland, T., 2012. Circulating cytokine concentrations are not associated with major depressive disorder in a 
community-based cohort. Gen. Hosp. Psychiatry 34, 262–267. 
https://doi.org/10.1016/j.genhosppsych.2012.01.017 
Eller, T., Vasar, V., Shlik, J., Maron, E., 2009. Effects of bupropion augmentation on pro-inflammatory cytokines 
in escitalopram-resistant patients with major depressive disorder. J. Psychopharmacol. Oxf. Engl. 23, 854–
858. https://doi.org/10.1177/0269881108091077 
Fekadu, A., Wooderson, S.C., Markopoulo, K., Donaldson, C., Papadopoulos, A., Cleare, A.J., 2009a. What 
happens to patients with treatment-resistant depression? A systematic review of medium to long term 
outcome studies. J. Affect. Disord. 116, 4–11. doi: 10.1016/j.jad.2008.10.014 
Fekadu, A., Wooderson, S.C., Markopoulou, K., Cleare, A.J., 2009b. The Maudsley Staging Method for 
treatment-resistant depression: prediction of longer-term outcome and persistence of symptoms. J. Clin. 
Psychiatry 70, 952–957. https://doi.org/10.4088/JCP.08m04728 
Fineberg, N.A., Haddad, P.M., Carpenter, L., Gannon, B., Sharpe, R., Young, A.H., Joyce, E., Rowe, J., Wellsted, 
D., Nutt, D.J., Sahakian, B.J., 2013. The size, burden and cost of disorders of the brain in the UK. J. 
Psychopharmacol. Oxf. Engl. 27, 761–770. https://doi.org/10.1177/0269881113495118 
Folstein, M.F., Robins, L.N., Helzer, J.E., 1983. The Mini-Mental State Examination. Arch. Gen. Psychiatry 40, 
812. 
Fornaro, M., Martino, M., Battaglia, F., Colicchio, S., Perugi, G., 2011. Increase in IL-6 levels among major 
depressive disorder patients after a 6-week treatment with duloxetine 60 mg/day: a preliminary 
observation. Neuropsychiatr. Dis. Treat. 7, 51–56. https://doi.org/10.2147/NDT.S16382 
Gadad, B.S., Jha, M.K., Czysz, A., Furman, J.L., Mayes, T.L., Emslie, M.P., Trivedi, M.H., 2018. Peripheral 
biomarkers of major depression and antidepressant treatment response: Current knowledge and future 
outlooks. J. Affect. Disord. 233, 3–14. https://doi.org/10.1016/j.jad.2017.07.001 
Grosse, L., Ambrée, O., Jörgens, S., Jawahar, M.C., Singhal, G., Stacey, D., Arolt, V., Baune, B.T., 2016. Cytokine 
levels in major depression are related to childhood trauma but not to recent stressors. 
Psychoneuroendocrinology 73, 24–31. https://doi.org/10.1016/j.psyneuen.2016.07.205 
Hall, J.R., Wiechmann, A., Edwards, M., Johnson, L.A., O’Bryant, S.E., 2016. IL-7 and Depression: The importance 
of gender and blood fraction. Behav. Brain Res. 315, 147–149. https://doi.org/10.1016/j.bbr.2016.08.026 
Hamilton, M., 1960. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 23, 56–62. 
Hannestad, J., DellaGioia, N., Bloch, M., 2011. The effect of antidepressant medication treatment on serum 
levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacol. Off. Publ. Am. Coll. 
Neuropsychopharmacol. 36, 2452–2459. https://doi.org/10.1038/npp.2011.132 
Hatch, S.L., Frissa, S., Verdecchia, M., Stewart, R., Fear, N.T., Reichenberg, A., Morgan, C., Kankulu, B., Clark, J., 
Gazard, B., Medcalf, R., SELCoH study team, Hotopf, M., 2011. Identifying socio-demographic and 
socioeconomic determinants of health inequalities in a diverse London community: the South East London 
Community Health (SELCoH) study. BMC Public Health 11, 861. https://doi.org/10.1186/1471-2458-11-861 
Husain, M.I., Strawbridge, R., Stokes, P.R., Young, A.H., 2017. Anti-inflammatory treatments for mood 
disorders: Systematic review and meta-analysis. J. Psychopharmacol. 31, 1137–1148. 
https://doi.org/10.1177/0269881117725711 
Köhler, C.A., Freitas, T.H., Stubbs, B., Maes, M., Solmi, M., Veronese, N., de Andrade, N.Q., Morris, G., 
Fernandes, B.S., Brunoni, A.R., Herrmann, N., Raison, C.L., Miller, B.J., Lanctôt, K.L., Carvalho, A.F., 2018. 
Peripheral Alterations in Cytokine and Chemokine Levels After Antidepressant Drug Treatment for Major 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
Depressive Disorder: Systematic Review and Meta-Analysis. Mol. Neurobiol. 55, 4195–4206. 
https://doi.org/10.1007/s12035-017-0632-1 
Kornstein, S.G., Schneider, R.K., 2001. Clinical features of treatment-resistant depression. J. Clin. Psychiatry 62, 
18. 
Kroenke, K., Spitzer, R.L., 2002. The PHQ-9: A New Depression Diagnostic and Severity Measure. Psychiatr. Ann. 
32, 509–515. https://doi.org/10.3928/0048-5713-20020901-06 
Lee, Y., Ragguett, R.-M., Mansur, R.B., Boutilier, J.J., Rosenblat, J.D., Trevizol, A., Brietzke, E., Lin, K., Pan, Z., 
Subramaniapillai, M., Chan, T.C.Y., Fus, D., Park, C., Musial, N., Zuckerman, H., Chen, V.C.-H., Ho, R., Rong, 
C., McIntyre, R.S., 2018. Applications of machine learning algorithms to predict therapeutic outcomes in 
depression: A meta-analysis and systematic review. J. Affect. Disord. 241, 519–532. 
https://doi.org/10.1016/j.jad.2018.08.073 
Lehto, S.M., Huotari, A., Niskanen, L., Herzig, K.-H., Tolmunen, T., Viinamäki, H., Koivumaa-Honkanen, H., 
Honkalampi, K., Sinikallio, S., Ruotsalainen, H., Hintikka, J., 2010. Serum IL-7 and G-CSF in major depressive 
disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 34, 846–851. 
https://doi.org/10.1016/j.pnpbp.2010.03.033 
Lewis, G., Pelosi, A.J., Araya, R., Dunn, G., 1992. Measuring psychiatric disorder in the community: a 
standardized assessment for use by lay interviewers. Psychol. Med. 22, 465–486. 
https://doi.org/10.1017/S0033291700030415 
Li, H., Sagar, A.P., Kéri, S., 2018. Microglial markers in the frontal cortex are related to cognitive dysfunctions in 
major depressive disorder. J. Affect. Disord. doi: 10.1016/j.jad.2018.08.021. 
Maes, M., Bosmans, E., De Jongh, R., Kenis, G., Vandoolaeghe, E., Neels, H., 1997. Increased serum IL-6 and IL-1 
receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 9, 
853–858. https://doi.org/10.1006/cyto.1997.0238 
Maes, M., Kubera, M., Mihaylova, I., Geffard, M., Galecki, P., Leunis, J. C., Berk, M., 2013. Increased 
autoimmune responses against auto-epitopes modified by oxidative and nitrosative damage in depression: 
implications for the pathways to chronic depression and neuroprogression. J Aff Disord. 149(1-3), 23-29. 
doi: 10.1016/j.jad.2012.06.039 
Maes, M., Kubera, M., Obuchowiczwa, E., Goehler, L., Brzeszcz, J., 2011. Depression’s multiple comorbidities 
explained by (neuro)inflammatory and oxidative & nitrosative stress pathways. Neuroendocrinol. Lett. 32, 
7–24.  
Miller, G., Rohleder, N., Cole, S.W., 2009. Chronic interpersonal stress predicts activation of pro-and anti-
inflammatory signaling pathways six months later. Psychosom Med. 71(1): 57. doi: 
10.1097/PSY.0b013e318190d7de. 
Raison, C.L., Felger, J.C., Miller, A.H., 2013. Inflammation and treatment resistance in major depression: the 
perfect storm. Psychiatr. Times 30, 17–17. 
Salvi, F., Miller, M.D., Grilli, A., Giorgi, R., Towers, A.L., Morichi, V., Spazzafumo, L., Mancinelli, L., Espinosa, E., 
Rappelli, A., Dessì-Fulgheri, P., 2008. A manual of guidelines to score the modified cumulative illness rating 
scale and its validation in acute hospitalized elderly patients. J. Am. Geriatr. Soc. 56, 1926–1931. 
https://doi.org/10.1111/j.1532-5415.2008.01935.x 
Schaefer, M., Sarkar, S., Schwarz, M., Friebe, A., 2016. Soluble Intracellular Adhesion Molecule-1 in Patients 
with Unipolar or Bipolar Affective Disorders: Results from a Pilot Trial. Neuropsychobiology 74, 8–14. 
https://doi.org/10.1159/000446919 
Sheehan, D.V., Lecrubier, Y., Sheehan, K.H., Amorim, P., Janavs, J., Weiller, E., Hergueta, T., Baker, R., Dunbar, 
G.C., 1998. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of 
a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 59 Suppl 20, 22-
33;quiz 34-57. 
Simes, R.J., 1986. An improved Bonferroni procedure for multiple tests of significance. Biometrika 73, 751–754. 
https://doi.org/10.1093/biomet/73.3.751 
Strawbridge, R., Arnone, D., Danese, A., Papadopoulos, A., Herane Vives, A., Cleare, A.J., 2015. Inflammation 
and clinical response to treatment in depression: A meta-analysis. Eur. Neuropsychopharmacol. 25, 1532–
1543. https://doi.org/10.1016/j.euroneuro.2015.06.007 
Strawbridge, R., Young, A.H., Cleare, A.J., 2018. Inflammation as a Marker of Clinical Response to Treatment: A 
Focus on Treatment-Resistant Depression, in: Inflammation and Immunity in Depression. Elsevier, pp. 473–
487. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
Strawbridge, R., Young, A.H., Cleare, A.J., 2017. Biomarkers for depression: recent insights, current challenges 
and future prospects [WWW Document]. Neuropsychiatr. Dis. Treat. https://doi.org/10.2147/NDT.S114542 
Streiner, D.L., Norman, G.R., 2011. Correction for multiple testing: is there a resolution? Chest 140, 16–18. 
https://doi.org/10.1378/chest.11-0523 
Takeshita, Y., Ransohoff, R.M., 2012. Inflammatory cell trafficking across the blood-brain barrier: chemokine 
regulation and in vitro models. Immunol. Rev. 248, 228–239. https://doi.org/10.1111/j.1600-
065X.2012.01127.x 
Trevino, K., 2012. Defining and Differentiating Treatment-Resistant Depression (Thesis). 
Uher, R., Tansey, K.E., Dew, T., Maier, W., Mors, O., Hauser, J., Dernovsek, M.Z., Henigsberg, N., Souery, D., 
Farmer, A., McGuffin, P., 2014. An inflammatory biomarker as a differential predictor of outcome of 
depression treatment with escitalopram and nortriptyline. Am. J. Psychiatry 171, 1278–1286. 
https://doi.org/10.1176/appi.ajp.2014.14010094 
Vergunst, F.K., Fekadu, A., Wooderson, S.C., Tunnard, C.S., Rane, L.J., Markopoulou, K., Cleare, A.J., 2013. 
Longitudinal course of symptom severity and fluctuation in patients with treatment-resistant unipolar and 
bipolar depression. Psychiatry Res. 207, 143–149. https://doi.org/10.1016/j.psychres.2013.03.022 
Wooderson, S.C., Fekadu, A., Markopoulou, K., Rane, L.J., Poon, L., Juruena, M.F., Strawbridge, R., Cleare, A.J., 
2014. Long-term symptomatic and functional outcome following an intensive inpatient multidisciplinary 
intervention for treatment-resistant affective disorders. J. Affect. Disord. 166, 334–342. 
https://doi.org/10.1016/j.jad.2014.05.013 
Wooderson, S.C., Juruena, M.F., Fekadu, A., Commane, C., Donaldson, C., Cowan, M., Tomlinson, M., Poon, L., 
Markopoulou, K., Rane, L., Donocik, J., Tunnard, C., Masterson, B., Cleare, A.J., 2011. Prospective evaluation 
of specialist inpatient treatment for refractory affective disorders. J. Affect. Disord. 131, 92–103. 
https://doi.org/10.1016/j.jad.2010.11.002 
 
 
 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
Table 1   TRD and non-depressed control participant characteristics  
 
 
 
 
Controls  
n=36 
TRD  
n=36 
Responders 
n=20 
Non-responders  
 n=16 
   p-value         
  * 
Gender  
n female (%)  21 (58%)  21 (58%)  11 (55%)  10 (63%)  
 
    
Age  
Mean age (range) 54.5 (28-80)  53.8 (26-82)  55.8 (40-78)  51.1 (26-82)  
 
BMI 
Mean BMI (range) 28.2 (20-42)  29.1 (18-46)  29.4 (21-46)  28.6 (18-44)  
 
Regular medications  
Mean number (range)   
  
5.6 (3-10)
a
 5.6 (3-10)  5.5 (3-10)
 
 
 
Medication changes ** 
Mean number (range)  4.2 (1-9)
b
 3.9 (1-6)  4.6 (1-9)
 
 
 
Baseline depression severity 
Mean HAM-D score (range)  21.8 (10-32)  20.5 (10-32)  22.9 (12-32)  
 
Discharge depression severity 
Mean HAM-D score (range)  12.2 (0-22)  7.5 (0-16)  16.3 (10-22)  
 
<0.001 
Long-term depression severity 
Mean HAM-D score (range)  
 
14.2 (5-29)
c
 10.7 (5-19)  17.27 (10-29)  
 
 
Long-term good/poor outcome 
n good outcome (%)  14 (50%)
c
 10 (71%)  4 (29%)  
 
  0.028 
Treatment-resistance 
Mean MSM score (range)  11.8 (8-15)  11.4 (8-14)  12.1 (8-15)  
 
Age of onset (mood disorder) 
Mean age (range)  33.1 (9-61)  38.7 (11-61)  28 (9-49)  
 
Lifetime psychosis  
n psychosis (%)  20 (55%)  11 (55%)  9 (56%)  
 
Childhood trauma severity 
Mean CTQ score (range)   57.1 (34-123)
d
 50.7 (36-77)  66.1 (34-123)  
 
Physical illness  
n illness(%)   17 (47%)  10 (50%)  7 (44%)  
 
Cognitive performance   
Mean MMSE score (range)  27.4 (18-30)  26.5 (18-30)  28.1 (20-30)  
 
  
Measurements reported from baseline assessment unless otherwise stated.  
* p-value, denoting difference between groups (either TRD versus control, or responder versus non-responder; the only 
significant differences in characteristics were between responders and non-responders). Differences are non-significant unless 
stated. 
** number of changes in medication with inpatient treatment (i.e. starting or stopping any medication adds 1 to the count).  
a 
n=35 (20 responders, 15 non-responders) 
b
 n=32 (17 responders, 15 non-responders) 
c
 n=28 (14 responders, 14 non-responders)  
d
 n=27 (16 responders, 11 non-responders). 
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Table 2: Baseline inflammation in TRD and control groups 
  
Protein   Control group    TRD group     OR 
      95% CI 
Lower    Upper         
 
   X
2
 
p      adj. p 
  lg-mean   SD    lg-mean   SD 
TNFα 0.376 0.163 0.370 0.188 0.965 0.596 1.562 0.021 0.896 0.931 
IL-6 -0.140 0.315 0.016 0.400 1.811 0.996 3.293 4.649 0.020 0.042 
CRP 6.570 0.568 6.415 0.697 0.737 0.433 1.254 1.322 0.572 0.672 
IL-10 -0.641 0.408 -0.498 0.300 1.502 0.878 2.570 2.676 0.271 0.410 
IL-8 0.935 0.176 1.348 0.592 5.858 1.551 22.133 16.609 0.002 0.007 
IL-12 2.001 0.222 2.110 0.249 1.646 0.968 2.800 3.880 0.025 0.048 
IL-7 1.165 0.222 1.142 0.183 0.907 0.584 1.408 0.192 0.681 0.766 
IL-15 0.319 0.093 0.341 0.135 1.154 0.766 1.739 0.487 0.492 0.633 
IL-16 2.228 0.168 2.352 0.219 1.688 1.025 2.781 5.310 0.031 0.056 
IL-17 0.157 0.402 0.157 0.348 1.000 0.617 1.620 0.000 0.998 0.998 
MCP1 2.406 0.188 2.313 0.159 0.506 0.277 0.927 5.950 0.010 0.025 
MCP4* 1.800 0.222 2.135 0.252 5.673 1.975 16.29 23.70 0.001 0.025 
Mip1b 2.083 0.153 2.129 0.298 1.250 0.752 2.075 0.770 0.405 0.576 
Eotaxin* 1.969 0.179 2.252 0.166 5.410 2.038 14.363 26.54 0.001 0.005 
sICAM1 5.824 0.267 5.577 0.134 0.132 0.034 0.507 23.701 0.001 0.005 
sVCAM1 5.905 0.289 5.602 0.128 0.045 0.005 0.422 30.433 0.005 0.015 
SAA 6.826 0.516 6.671 0.719 0.656 0.346 1.242 1.826 0.173 0.292 
TARC 2.282 0.237 2.464 0.336 2.636 1.258 5.521 9.286 0.012 0.027 
IP-10* 2.200 0.166 2.533 0.206 5.407 1.990 14.690 27.09 0.001 0.005 
IFNγ 0.740 0.310 0.752 0.265 1.181 0.704 1.981 0.429 0.523 0.642 
Eotaxin3* 0.315 0.491 1.252 0.279 5.791 2.040 16.440 29.53 0.001 0.005 
Mip1a* 0.413 0.447 1.338 0.439 5.837 2.003 17.010 29.54 0.001 0.005 
IL-5 -1.110 0.627 -0.275 0.532 5.385 1.810 16.025 24.065 0.004 0.014 
TNFβ -0.990 0.439 -1.271 0.392 0.449 0.240 0.842 8.358 0.010 0.025 
IL-12p70 -1.214 0.524 -1.290 0.476 0.808 0.464 1.405 0.586 0.449 0.606 
IL-4 -2.025 0.371 -1.964 0.762 1.104 0.699 1.743 0.182 0.730 0.788 
IFNα* -0.308 0.472 -0.429 0.262 0.704 0.425 1.166 3.058 0.273 0.410 
 
Bold text indicates significant effects.  
* due to separation between patient and control data distributions, a conditional logistic regression with firth penalisation was 
undertaken 
lg-mean=log-transformed mean value, SD=standard deviation, OR=odds ratio (exponent of beta coefficient), 95% CI=95% 
confidence intervals, p = unadjusted p value before Simes control for multiple comparisons, adj. p= p value after Simes control for 
multiple comparisons.   
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Figure 1: Inflammatory marker increases during inpatient treatment 
Comparison of protein levels between controls (white) and TRD patients at pre-treatment (black) and post-
treatment (grey) for (A) IL-10, (B) MCP1, (C) sICAM1 and (D) IFNy. Bars denote log transformed mean values 
and error bars as standard error of the mean. N.B. axes do often not begin at 0 to express group differences 
clearly for each protein.   
* = significant differences at p < 0.05; ** = significant differences at p < 0.01. 
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Figure 2: Inflammatory markers associated with subsequent poor long-term outcomes 
Comparison of post-treatment protein levels and poor outcome in the year following discharge from the 
inpatient service for (A) IL-6 and (B) CRP. Displayed are biomarker levels for patients with a good outcome 
(grey) and poor outcome (black) at post-treatment as well as pre-treatment and control levels (white). Bars 
denote log-transformed mean values and error bars as standard error of the mean. N.B. axes do often not 
begin at 0 to express group differences clearly for each protein.   
* = significant differences at p < 0.05.  
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Figure 3: Baseline cytokine correlations with retrospective severity of treatment resistance 
Significant associations (all p < 0.05) between treatment-resistance in the current episode assessed using the 
Maudsley Staging Method (MSM) and levels of A) TNFa, (B) CRP, (C) IL-6, (D) IL-12 and (E) Mip1b assessed at 
inpatient admission. N.B. axes do often not begin at 0 to express group differences clearly for each protein.   
  
